Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Conditions
Phelan McDermid Syndrome
Interventions
Recombinant human Growth hormone
Drug
Lead sponsor
Swathi Sethuram
Other
Eligibility
2 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Colon Cancer, Rectal Cancer
Interventions
Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Conditions
Growth Hormone Deficiency
Interventions
Recombinant Human Growth Hormone, Recombinant Human IGF-1
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause

NCT02404792
Conditions
HIV, Inflammation, Obesity, Aging, Biological
Interventions
High-intensity cardiovascular and resistance exercise, Moderate-intensity cardiovascular and resistance exercise
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Insulin Resistance, Hyperglycemia
Interventions
insulin-like growth factor I
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Conditions
Acromegaly
Interventions
Debio 4126, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Terminated Phase 1Phase 2 Interventional Results available

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

NCT03175978
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, With Excess of Blasts
Interventions
IGF/MTX
Drug
Lead sponsor
IGF Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Conditions
Acromegaly, Growth Hormone Deficiency, Pituitary Disease
Interventions
Recombinant human growth hormone, Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions
rhIGF-1 (mecasermin) for a period of 86 weeks
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Brisbane, California
Conditions
IGF1 Deficiency
Interventions
Increlex®
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
2 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Orange, California • Miami, Florida • Cincinnati, Ohio + 2 more
Conditions
Crohns Disease
Interventions
Examinations
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
MM-151, MM-121, MM-141, trametinib
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Peak Bone Mass

NCT01301183
Conditions
Anorexia Nervosa
Interventions
RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Intrauterine Growth Retardation
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Months to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Hyde Park, New York + 2 more
Completed Phase 2Phase 3 Interventional Results available

Bone Loss in Women With Anorexia Nervosa

NCT00089843
Conditions
Anorexia Nervosa
Interventions
Testosterone, Actonel (risedronate), Placebo Actonel (risedronate), Placebo testosterone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas